REGN Stock Summary and Trading Ideas (Regeneron Pharmaceuticals | NASDAQ:REGN)

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

What symbol and exchange does Regeneron Pharmaceuticals shares trade?

Regeneron Pharmaceuticals trades on the NASDAQ stock market under the symbol REGN.

What is Regeneron Pharmaceuticals stock price doing today?

As of April 28, 2026, REGN stock price declined to $731.77 with 504,201 million shares trading.

What is Regeneron Pharmaceuticals's Beta?

REGN has a beta of 0.66, meaning it tends to be less sensitive to market movements. REGN has a correlation of 0.05 to the broad based SPY ETF.

How much is Regeneron Pharmaceuticals worth?

REGN has a market cap of $76.72 billion. This is considered a Large Cap stock.

How much money does Regeneron Pharmaceuticals make?

Last quarter Regeneron Pharmaceuticals reported $4 billion in Revenue and $11.44 earnings per share. This beat revenue expectation by $86 million and exceeded earnings estimates by $1.75.

What is the highest and lowest price Regeneron Pharmaceuticals traded in the last 3 year period?

In the last 3 years, REGN traded as high as $1,211.20 and as low as $476.49.

What are the top ETFs holding Regeneron Pharmaceuticals?

The top ETF exchange traded funds that REGN belongs to (by Net Assets): VTI, VOO, QQQ, IVV, SPY.

Is Regeneron Pharmaceuticals (REGN) a good investment?

REGN has underperformed the market in the last year with a price return of +22.0% while the SPY ETF gained +30.6%. REGN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -5.0% and -2.0%, respectively, while the SPY returned +2.6% and +3.7%, respectively.

What are the support and resistance levels for Regeneron Pharmaceuticals (REGN)?

REGN support price is $732.43 and resistance is $756.46 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that REGN shares will trade within this expected range on the day.